Results 131 to 140 of about 85,257 (242)

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

PKM2 Lactylation Promotes Colorectal Cancer Vasculogenic Mimicry and Bevacizumab Resistance by Facilitating FOSL1 Super-enhancer Formation. [PDF]

Cancer Res
Li W, Peng J, He J, Liao L, Kang D, Zhang W, Wang W, Wang R, Wang S, Liao Y, Yu L, Ou Q, Fang Y, Wu X, Ding P, Pan Z, Zhou C, Lin J.   +17 more
europepmc   +1 more source

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Indications and outcome of intravitreal bevacizumab injection in a Community Eye Hospital, Nepal. [PDF]

BMC Ophthalmol
Thakali S, Shrestha M, Gauchan A, Gurung HB.   +3 more
europepmc   +1 more source

Bevacizumab for Radiation-Induced (Radiculo)plexopathy. [PDF]

Eur J Neurol
Picca A, Lenglet T, Vandendries C, Simon JM, Ducloie M, Maisonobe T, Ricard D, Psimaras D.   +7 more
europepmc   +1 more source

Potential Role of Liver Transplantation for Child–Pugh Class A Hepatocellular Carcinoma: Prognosis and Medical Expenditure in Japan—A Retrospective Single‐Center Study

Hepatology Research, EarlyView.
Among patients with CP‐A HCC initially within the Japan criteria, some lose oncological eligibility for LT before hepatic decompensation. Further studies are needed to identify baseline factors associated with poor outcomes and to evaluate their relevance to future LT candidacy.
Akihiro Seki, Tomoyoshi Chiba, Shintaro Yagi, Rika Horii, Noboru Takata, Hiroki Nomura, Masaki Miyazawa, Tomoyuki Hayashi, Takeshi Terashima, Shinichi Nakanuma, Mitsuyoshi Okazaki, Satoshi Takada, Tatsuya Yamashita, Masao Honda, Hajime Takatori, Tetsuro Shimakami, Taro Yamashita   +16 more
wiley   +1 more source

Updates and controversies in contemporary grading of clear cell renal cell carcinoma and papillary renal cell carcinoma

Histopathology, EarlyView.
New concepts, innovations and some issues have emerged since the adoption a decade ago of WHO/ISUP grading for CCRCC and PRCC. Continued use of the WHO/ISUP grading for CCRCC and PRCC has been upheld by newer studies, and practice guidance for some of the grading issues, where data are available, is provided.
Gladell P. Paner, Mahul. B. Amin, Jung Woo Kwon, Liang Cheng, Holger Moch   +4 more
wiley   +1 more source

VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC. [PDF]

J Immunother Cancer
Roulleaux-Dugage M, Yurchenko A, Nikolaev S, Nabet B, Corgnac S, Anquetil C, Srivastava MK, Gayevskiy V, McNally V, Mezquita L, Perfettini JL, Mouraud S, Massard C, Besse B, Loriot Y, Marabelle A, Chaput N, Auclin E.   +17 more
europepmc   +1 more source

The Emerging Role of UCHL1 in Neurological and Musculoskeletal Diseases

Immunology &Cell Biology, EarlyView.
UCHL1‐associated pathology. The pathological role of UCHL1 in multisystem diseases, including cancer, neurological, musculoskeletal and cardiovascular disorders. ABSTRACT Ubiquitin C‐terminal hydrolase L1 (UCHL1) is a highly conserved deubiquitinating enzyme that has transitioned from being viewed as a “brain‐specific” protein to a global regulator of ...
Ru Feng, Xiu Zhong, Jianjun Li, Adrian A. Achuthan   +3 more
wiley   +1 more source

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. [PDF]

PLoS One
Nishioka C, Tahata Y, Maesaka K, Kai M, Shirai K, Murai K, Makino Y, Saito Y, Nozaki Y, Nakabori T, Ishida H, Yakushijin T, Iio S, Tatsumi N, Imanaka K, Kakita N, Sakamori R, Hosui A, Miyazaki M, Matsumoto K, Nakahara M, Doi Y, Sakakibara M, Hikita H, Kodama T, Takehara T.   +25 more
europepmc   +1 more source